文献速递银屑病与炎症性皮肤病自身免疫性与大疱性皮肤病

阿尼鲁单抗快速有效治疗难治性皮肤型红斑狼疮并与血液转录组和细胞标志物变化相关

Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
PubMed 文献 · Br J Dermatol · 2023-01-01

这项前瞻性单中心研究评估了阿尼鲁单抗治疗7例难治性黏膜皮肤系统性红斑狼疮患者,其中盘状红斑狼疮5例、冻疮样红斑狼疮1例、亚急性皮肤型红斑狼疮1例。中位CLASI-A从基线17降至1个月6(P=0.016)和3个月0(P<0.001),3个月中位降幅60%。临床应答伴随M1.2模块干扰素刺激基因的离散抑制及中间型单核细胞降至正常水平。

要点

  • 阿尼鲁单抗使难治性皮肤型红斑狼疮CLASI-A快速持续下降,3个月中位降幅60%。
  • 临床应答与M1.2模块干扰素刺激基因的离散抑制及中间型单核细胞下降相关。
  • 1例患者因严重带状疱疹停药。

核心结论

  • 数据表明阿尼鲁单抗对盘状红斑狼疮和利妥昔单抗耐药的皮肤型红斑狼疮快速有效。
  • 应答与部分干扰素刺激基因抑制及中间型单核细胞下降相关,抑制全部干扰素刺激基因或更广泛SLE血液转录组并非应答所必需。

研究设计与样本

  • 前瞻性单中心研究,纳入7例难治性黏膜皮肤系统性红斑狼疮患者,其中盘状红斑狼疮5例、冻疮样红斑狼疮1例、亚急性皮肤型红斑狼疮1例。
  • 中位既往治疗数为6种(范围3-15),7例中6例既往使用过利妥昔单抗。
  • 在基线、1个月、3个月和6个月进行CLASI活动度评分、健康相关生活质量、96探针TaqMan®基因表达分析和八色流式细胞术。

主要发现

  • 中位CLASI-A从基线17快速持续改善至1个月6(P=0.016)和3个月0(P<0.001)。
  • 3个月时CLASI-A中位降幅为60%。
  • DLQI评分(P<0.001)、EuroQol 5D视觉模拟量表(P=0.002)及LupusQoL疲劳、形象和计划领域(P≤0.05)均显著改善。
  • 临床应答伴随SLE血液转录组模块M1.2干扰素刺激基因的离散抑制,其他干扰素模块下调更为多变。
  • 髓系和炎症注释基因在整个治疗期间保持上调;中间型单核细胞(CD14++CD16+)降至正常水平(P=0.014),其他流式亚群无实质性变化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observations with rituximab suggest B-cell independent mechanisms of cutaneous lupus erythematosus (CLE) in systemic lupus erythematosus (SLE), especially discoid lupus erythematosus (DLE). Type-I interferon receptor blockade with anifrolumab shows efficacy in SLE, but efficacy for cutaneous disease of specific morphologies has not been studied. Interferon has pleotropic immune effects and it is unknown which of these are critical to therapeutic response. OBJECTIVES: We evaluated clinical efficacy and quality-of-life impact of type-I interferon-blockade in: (i) rituximab-refractory CLE; (ii) DLE and other morphologies and (iii) transcriptomic and flow cytometric biomarkers. METHODS: We conducted a prospective single-centre study of anifrolumab in refractory mucocutaneous SLE. CLE Disease Area and Severity Index (CLASI) activity score, health-related quality of life, 96-probe TaqMan® gene expression analysis capturing key SLE blood transcriptome signatures, and eight-colour flow cytometry were undertaken at baseline, 1, 3 and 6 months. RESULTS: Seven patients [DLE (n = 5), chilblain lupus erythematosus (n = 1), subacute CLE (n = 1)] were evaluated. The median number of prior therapies was six (range 3-15), including rituximab in six of seven patients. Median CLASI-A showed rapid and sustained improvement from 17 at baseline to 6 (P = 0.016) at 1 month and 0 (P < 0.001) by 3 months. The median percentage reduction in CLASI-A at 3 months was 60%. Significant improvements were observed in Dermatology Life Quality Index scores (P < 0.001), EuroQol 5D visual analogue scale (P = 0.002) and LupusQoL fatigue, image and planning domains (P ≤ 0.05). One patient discontinued treatment owing to severe herpes zoster. Clinical responses paralleled discrete suppression of interferon-stimulated genes (ISGs) from SLE blood transcriptome module M1.2 with more varied downregulation in other interferon modules. Myeloid and inflammation-annotated genes remained upregulated throughout treatment. Intermediate monocytes (CD14++CD16+) reduced to normal levels during therapy (P = 0.014), while other flow subsets showed no substantive changes. CONCLUSIONS: These data indicate rapid efficacy of anifrolumab in DLE and rituximab-resistant CLE. Response is associated with suppression of a subset of ISGs and decline in intermediate monocytes. Suppression of all ISGs or the wider SLE blood transcriptome is not required for response.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Carter LM, Wigston Z, Laws P, et al. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol. 2023. PMID: 36944572. doi:10.1093/bjd/ljad089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。